Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC005165 | Panoply™ Human F11 Knockdown Stable Cell Line | Inquiry |
| CSC-DC017890 | Panoply™ Human ZNF160 Knockdown Stable Cell Line | Inquiry |
| CSC-SC005165 | Panoply™ Human F11 Over-expressing Stable Cell Line | Inquiry |
| CSC-SC017890 | Panoply™ Human ZNF160 Over-expressing Stable Cell Line | Inquiry |
| CLOE-1538 | Human F11 HEK293 Cell Lysate | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD18136Z | Human ZNF160 adenoviral particles | Inquiry |
| LV12077L | human F11 (NM_000128) lentivirus particles | Inquiry |
| LV30440L | human ZNF160 (NM_033288) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH043139 | shRNA set against Rat F11(NM_001047848.1) | Inquiry |
| SHH043147 | shRNA set against Human F11(NM_000128.3) | Inquiry |
| SHH043193 | shRNA set against Mouse F11(NM_028066.1) | Inquiry |
| SHH224376 | shRNA set against Human ZNF160(NM_033288.3) | Inquiry |
| SHH288373 | shRNA set against Human F11 (NM_000128.3) | Inquiry |
| SHH288377 | shRNA set against Mouse F11 (NM_028066.1) | Inquiry |
| SHH288381 | shRNA set against Rat F11 (NM_001047848.1) | Inquiry |
| SHH450472 | shRNA set against Mouse Zfp160 (NM_145483.2) | Inquiry |
| SHH453164 | shRNA set against Human ZNF160 (NM_198893.2) | Inquiry |
| SHW012099 | shRNA set against Danio rerio VASNB (NM_001110762) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFH021716 | Human ZNF160 cDNA Clone(NM_001102603.1) | Inquiry |
| CDFR004861 | Rat F11 cDNA Clone(NM_001047848.1) | Inquiry |
| MiUTR1H-11488 | ZNF160 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-12982 | ZFP160 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-01793 | F11 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-02481 | F11 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-03338 | ZNF160 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-03339 | ZNF160 miRNA 3'UTR clone | Inquiry |
| CDCB173574 | Danio rerio VASNB ORF Clone (NM_001110762) | Inquiry |
| CDCB180679 | Rabbit F11 ORF clone (NM_001082792.1) | Inquiry |
| CDCH404947 | Human ZNF160 ORF clone(NM_033288.3) | Inquiry |
| CDCL184130 | Human F11 ORF clone(NM_000128.3) | Inquiry |
| CDCL184131 | Mouse F11 ORF clone(NM_028066.1) | Inquiry |
| CDCR347289 | Human ZNF160 ORF Clone(NM_001102603.1) | Inquiry |
| CDCR371934 | Rat F11 ORF Clone(NM_001047848.1) | Inquiry |
| CDCS405443 | Human F11 ORF Clone (BC119014) | Inquiry |
Functions & Recent Research Progress
Coagulation factors are various protein components involved in the blood coagulation process. Its physiological role is to activate when blood vessels bleed, stick to platelets and fill the leaks on the blood vessels. Factor XI (F11) is essential for the normal function of the intrinsic pathway of blood coagulation. Factor XI is a key player in blood coagulation and therefore represents a potential target for antisense therapy. Moreover, F11 is required for the maintenance of endogenous pathways and plays a key role in the amplification of the coagulation cascade.
Figure 1. Coagulation cascade (Yahui Chen,2015)
The role of F11 in the coagulation cascade and thrombosis.
The coagulation cascade is a process in which a series of coagulation factors are sequentially activated to form fibrin. The coagulation cascade is initiated by the endogenous pathway (also known as the contact activation pathway) and the exogenous pathway (also known as the tissue factor pathway) to produce FXa, which is then produced by a common pathway to form thrombin (FIla), which ultimately forms fibrin. F11 is required for the maintenance of endogenous pathways and plays a key role in the amplification of the coagulation cascade. In the coagulation cascade, thrombin can feedbackly activate F11, which in turn promotes the production of thrombin. Thereby, the coagulation cascade is amplified. Therefore, a drug against the F11 target can block the endogenous pathway and inhibit the amplification of the coagulation cascade, thereby having an antithrombotic effect. Meanwhile, a large amount of thrombin dependent on F11a can be activated. The thrombin-activated fibrinolysis inhibitor (TAFI) down-regulates the fibrinolytic system.
F11 is essential for the normal function of the intrinsic pathway of blood coagulation. Nucleotide variants (rs3756008) in the promoter region of the F11 gene have recently been reported to be associated with venous thromboembolism. Scientists believe that the minor allele of rs3756008 in the F11 gene promoter can reduce its expression in the kidney.
F11 is a key player in blood clotting and therefore represents a potential target for antisense therapy. Although current treatment devices for venous thrombosis include the use of vitamin K antagonists, heparin and direct oral anticoagulants, these drugs have several important drawbacks. Antisense oligonucleotides are relatively short single-stranded nucleic acid sequences that hybridize to target messenger RNA (mRNA) and inhibit protein synthesis. The study found that Factor XI antisense oligonucleotides may be more effective at preventing the development and proliferation of thrombosis than conventional anticoagulants, and do not require factor measurement because the reduction in mRNA synthesis is dose dependent.
References: